Pancreatic Cancer Research

ResearcherCornell UniversityActive in the last 2 years

Quisette P. Janssen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-9353-8293; OpenAlex author ID A5058791475. Sources: OpenAlex.

Their work

Papers
30 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
148
Papers, trials and grants by year

2019: 1 paper · 2020: 2 papers · 2021: 3 papers · 2022: 8 papers · 2023: 3 papers · 2024: 4 papers · 2025: 5 papers · 2026: 4 papers

Papers 30

  1. The PREOPANC-2 trial in resectable and borderline resectable pancreatic cancer - Authors' reply. Co-author DOI 10.1016/s1470-2045(25)00729-6↗
  2. Prediction of resection after preoperative FOLFIRINOX in patients with localized pancreatic adenocarcinoma: a Trans-Atlantic Pancreatic Surgery (TAPS) Consorti… Co-author DOI 10.1093/jnci/djag033↗
  3. Staging Laparoscopy After Neoadjuvant Treatment for Pancreatic Cancer to Prevent Non-Therapeutic Laparotomy: Analysis in the PREOPANC-2 Randomized Trial. Co-author DOI 10.1097/sla.0000000000007025↗
  4. Thromboembolic Events During Perioperative Therapy for Resectable and Borderline Resectable Pancreatic Cancer in the PREOPANC-2 Trial. Co-author DOI 10.1200/jco-25-01935↗
  5. Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multice… Co-author DOI 10.1016/s1470-2045(25)00363-8↗
  6. Carbohydrate antigen 19-9 (CA19-9) response after induction FOLFIRINOX for locally advanced pancreatic cancer identifies patients who may benefit from surgical… Co-author DOI 10.1093/bjs/znaf011↗
  7. Delayed gastric emptying after pancreatic cancer surgery impacts time to start of adjuvant treatment but not overall survival: a post-hoc analysis of the PREOP… Co-author DOI 10.1093/bjs/znaf261↗
  8. Validation of the PANAMA Score for Survival and Benefit of Adjuvant Therapy in Patients With Resected Pancreatic Cancer after Neoadjuvant FOLFIRINOX. Co-author DOI 10.1097/sla.0000000000006650↗
  9. Surgical Complications in Patients with (borderline) Resectable Pancreatic Cancer after Neoadjuvant Therapy in the PREOPANC-2 Randomized Controlled Trial. Co-author DOI 10.1097/sla.0000000000006910↗
  10. Impact of a non-therapeutic laparotomy in patients with locally advanced pancreatic cancer treated with induction (m)FOLFIRINOX: Trans-Atlantic Pancreatic Surg… Co-author DOI 10.1093/bjs/znae033↗
  11. Improved Clinical Staging System for Localized Pancreatic Cancer Using the ABC Factors: A TAPS Consortium Study. Co-author DOI 10.1200/jco.23.01311↗
  12. Serum CEA as a Prognostic Marker for Overall Survival in Patients with Localized Pancreatic Adenocarcinoma and Non-Elevated CA19-9 Levels Treated with FOLFIRIN… Co-author DOI 10.1245/s10434-023-14680-0↗
  13. ASO Author Reflections: The Value of Serum CEA for Prognostication at Staging and Response Evaluation in Patients with Localized Pancreatic Adenocarcinoma and … Co-author DOI 10.1245/s10434-023-14815-3↗
  14. Diagnostic performance of endoscopic tissue acquisition for pancreatic ductal adenocarcinoma in the PREOPANC and PREOPANC-2 trials. Co-author DOI 10.1016/j.hpb.2023.04.018↗
  15. Genomic Biomarkers Associated with Response to Induction Chemotherapy in Patients with Localized Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-22-3089↗
  16. Surgical and Oncological Outcomes After Preoperative FOLFIRINOX Chemotherapy in Resected Pancreatic Cancer: An International Multicenter Cohort Study. Co-author DOI 10.1245/s10434-022-12387-2↗
  17. Real-world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma. First author DOI 10.1002/ijc.33916↗
  18. Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomised controlled trials. First author DOI 10.1016/j.ejca.2021.10.023↗
  19. Development and validation of the Massachusetts General Hospital/Memorial Sloan Kettering nomogram to predict overall survival of resected patients with pancre… Co-author DOI 10.1016/j.surg.2022.05.024↗
  20. FOLFIRINOX as Initial Treatment for Localized Pancreatic Adenocarcinoma: A Retrospective Analysis by the Trans-Atlantic Pancreatic Surgery Consortium. Co-author DOI 10.1093/jnci/djac018↗
  21. Alterations in Somatic Driver Genes Are Associated with Response to Neoadjuvant FOLFIRINOX in Patients with Localized Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/xcs.0000000000000212↗
  22. Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREO… Co-author DOI 10.1200/jco.21.02233↗
  23. Serum cytokine levels are associated with tumor progression during FOLFIRINOX chemotherapy and overall survival in pancreatic cancer patients. Co-author DOI 10.3389/fimmu.2022.898498↗
  24. Neoadjuvant Radiotherapy After (m)FOLFIRINOX for Borderline Resectable Pancreatic Adenocarcinoma: A TAPS Consortium Study. Co-author DOI 10.6004/jnccn.2022.7008↗
  25. Circulating TP53 mutations are associated with early tumor progression and poor survival in pancreatic cancer patients treated with FOLFIRINOX. Co-author DOI 10.1177/17588359211033704↗
  26. Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreati… First author DOI 10.1186/s12885-021-08031-z↗
  27. Added Value of Radiotherapy Following Neoadjuvant FOLFIRINOX for Resectable and Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis. Co-author DOI 10.1245/s10434-021-10276-8↗
  28. Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment. Co-author DOI 10.1001/jamaoncol.2020.3537↗
  29. Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer. Co-author DOI 10.3389/fonc.2020.00041↗
  30. Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. Co-author DOI 10.1093/jnci/djz073↗

Closest collaborators

The 25 strongest of 148 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Bas Groot Koerkamp · 24 shared papers, 2019–2026 · strength 3.73
  2. Marc G. Besselink · 23 shared papers, 2019–2026 · strength 3.56
  3. Casper H.J. van Eijck · 16 shared papers, 2019–2026 · strength 2.34
  4. Jacob L. van Dam · 12 shared papers, 2021–2026 · strength 2.00
  5. Alice Chia-Chi Wei · 12 shared papers, 2021–2026 · strength 1.99
  6. Johanna W. Wilmink · 14 shared papers, 2019–2026 · strength 1.96
  7. Marjolein Y.V. Homs · 13 shared papers, 2019–2026 · strength 1.89
  8. Geertjan van Tienhoven · 10 shared papers, 2019–2026 · strength 1.53
  9. Matthew H. G. Katz · 9 shared papers, 2019–2026 · strength 1.51
  10. Amer H. Zureikat · 8 shared papers, 2022–2026 · strength 1.45
  11. Laura R. Prakash · 8 shared papers, 2022–2026 · strength 1.45
  12. Ching-Wei David Tzeng · 8 shared papers, 2022–2026 · strength 1.45
  13. Thomas F. Stoop · 7 shared papers, 2024–2026 · strength 1.28
  14. Esther N. Dekker · 6 shared papers, 2024–2026 · strength 1.15
  15. Bert A. Bonsing · 8 shared papers, 2021–2026 · strength 1.13
  16. Rutger T. Theijse · 6 shared papers, 2024–2025 · strength 1.10
  17. Eileen Mary O'Reilly · 7 shared papers, 2020–2025 · strength 1.07
  18. Roeland F. de Wilde · 6 shared papers, 2021–2026 · strength 1.05
  19. Deesje Doppenberg · 6 shared papers, 2022–2024 · strength 1.00
  20. Hjalmar C. van Santvoort · 6 shared papers, 2021–2026 · strength 0.91
  21. Eva M M Verkolf · 4 shared papers, 2024–2026 · strength 0.76
  22. Gijs A. Patijn · 5 shared papers, 2021–2026 · strength 0.75
  23. Ignace H. J. T. de Hingh · 5 shared papers, 2021–2026 · strength 0.75
  24. William R. Jarnagin · 5 shared papers, 2022–2023 · strength 0.68
  25. Alessandro Paniccia · 5 shared papers, 2019–2025 · strength 0.67

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.